CD8 regulatory T cell therapy in transplantation: a new path to clinical success?
Yannick D. Muller, Julien Zuber · 2026
Read CD8 regulatory T cell therapy in transplantation: a new path to clinical success? by Yannick D. Muller, Julien Zuber (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13286856.txt.
Description
Yannick D. Muller and Julien Zuber review a new cell therapy aimed at calming the immune system after organ transplantation, using a less-studied class of regulatory T cells marked CD8. Published in 2026, the article sets this approach beside the better-known CD4 regulatory cells already in many transplant trials. A first-in-human trial, Eight-Treg, is testing the CD8 version in kidney recipients.
The cells are sorted from a candidate's own blood before transplant, grown for three weeks under conditions that preserve their calming identity, and returned as a living product. Earlier CD4 trials hinted that such therapy can safely reduce anti-rejection drug doses. Whether the CD8 route reaches routine care depends on trial results still to come.
Catalog record
| CREATOR | Yannick D. Muller, Julien Zuber |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |